Health Condition 1: K769- Liver disease, unspecified
Conditions
Interventions
Intervention1: Albumin with Midodrine: Dose: Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
Route of Administration: Intravenous
Duration of Therapy: 7 days
Fr
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: ACLF patients (as per APASL definition) with grade II/III ascites
Exclusion criteria
Exclusion criteria: 1. Age 75 years 2. Hepatocellular carcinoma 3. Extrahepatic portal vein obstruction 4. Non cirrhotic ascites 5. Serum creatinine >1.5mg/dl 6. Refractory septic shock 7. Beta blockersPortal vein thrombosis 8. Grade 3â??4 HE 9. Pregnancy or Lactation 10. Active variceal bleed 11. Respiratory, cardiac, renal failure 12. Uncontrolled hypertension 13. Severe coagulopathy 14. Refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of PICD at day 3 and day6Timepoint: Day 3 and Day 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in hemodynamic parameters at post paracentesisTimepoint: 1, 3 and 6 hour, Day 3, Day 6;Incidence of Hyponatremia, HE and AKI at day 3 and 6Timepoint: Day 3 and day 6;Increase in plasma renin activity at Day 3, Day 6Timepoint: Day 3 and day 6 | — |
Countries
India
Contacts
Public ContactDr Shiv Kumar Sarin
Institute of Liver and Biliary Sciences
Outcome results
None listed